Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation
Navneet S Majhail, J Douglas Rizzo, Stephanie Lee, Mahmoud Aljutts, Yoshiko Atsuta, Carmem Bonfim, Linda Burns, Naeem Chaudhri, Stella Davies, Shinichiro Okamoto, Adriona Seber, Gerard Socie, Jeff Szer, Maria Teresa Van Lint, John R Wingard, Andre Tichellii
Biology of Blood and Marrow Transplantation | ELSEVIER SCIENCE INC | Published : 2012
Awarded by Public Health Service from National Cancer Institute (NCI)
Awarded by NHLBI
Awarded by Office of Naval Research
Awarded by Health Resources and Services Administration (HRSA/DHHS)
Financial disclosure: The authors acknowledge the following members of the Late Effects Working Group of the Asia-Pacific Blood and Marrow Transplantation Group for their review of this article: Mickey Koh (Singapore), Jong Wook Lee (Korea), David Ma (Australia), and Tahir Shamsi (Pakistan). Sources of Support: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NEILBI), and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U-01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from AABB; Allos, Inc.; Amgen, Inc.; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US, Inc.; Be the Match Foundation; Biogen IDEC; BioMarin Pharmaceutical, Inc.; Biovitrum AB; Blood Center of Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow Foundation; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; ClinImmune Labs; CTI Clinical Trial and Consulting Services; Eisai, Inc.; Genentech, Inc.; Genzyme Corporation; Histogenetics, Inc.; HKS Medical Information Systems; Hospira, Inc.; Kirin Brewery Co., Ltd.; The Leukemia & Lymphoma Society; Merck & Company; The Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Miller Pharmacal Group; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Nature Publishing Group; Novartis Oncology; Oncology Nursing Society; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Pall Life Sciences; Pfizer Inc.; Schering Corporation; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, Inc.; StemSoft Software, Inc.; Sysmex America, Inc.; THERAKOS, Inc.; Vidacare Corporation; ViraCor Laboratories; ViroPharma, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government.